- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Intramatricial injection of anti-IL-17A Ab efficacious in nail psoriasis : CED study
Intramatricial injection of anti-IL-17A Ab efficacious in nail psoriasis : CED study1
Nail involvement is a common feature of psoriasis commonly overlooked by physicians. It affects approximately 10-78% of psoriasis patients with 5-10% of patients having isolated nail psoriasis.2 Its significant association with arthritis, its resistance to treatment and psychological stress it causes in patients makes it an important feature of psoriasis which needs attention and treatment. IL-17 monoclonal antibodies have been one of the successful biologicals in the treatment of psoriasis. Recently a study describing efficacy of intramatricial injection of anti-IL-17A Ab in nail psoriasis was published in the Clinical and Experimental Dermatology journal.
6 patients with psoriasis vulgaris and NP were recruited- 3 males and 3 females (age: 33.2± 11.1 years, skin psoriasis duration: 8.3± 4.1 years, NP duration: 3.2±1.5 years, PASI: 2.6±0.6). The number of involved fingernails was 9.2±1.3. All the patients received topical corticosteroids and/or vitamin D3 analogues without any systemic treatment in the past 3 months.
Each patient received local anaesthesia with 5% lidocaine and 1% tetracaine under occlusion for an hour in proximal nail fold. 3 severe nails of left hand were treated with intramatricial injections of secukinumab in different concentrations, 7.5mg/ml, 15mg/ml and 30mg/ml respectively formed by dilution with sterile water and preserved at 4℃. The needle was inserted from the two sides of the proximal nail fold in a 'V' pattern to inject 0.05 ml each side every time. Patients received 5-6 times treatments with a 2-week interval.
All enrolled nails were assessed with Nail Psoriasis Severity Index (NAPSI) score from baseline to week 12 fortnightly. Patients were followed up at week 24 after last treatment. The untreated symmetrical finger of right hand was considered as control.
At week 24, the mean improvement rate of NAPSI was 73.2% and 18.3% respectively (P<0.01) between the treated fingernails (18 fingernails) and the control. The mean improvement rate of NAPSI was 76.1%, 66.1% and 75.7% for secukinumab concentration of 7.5 mg/ml, 15 mg/ml and 30mg/ml respectively without any statistically significant difference in efficacy among the three concentrations.
The improvements seen in nail bed lesions (onycholysis, subungual hyperkeratosis and splinter hemorrhages) were superior to that in nail matrix lesions (nail plate crumbling). At week 24, the mean improvement rate of NAPSI of all the treated fingernails was 88.7% and 63.1% for nail bed and nail matrix respectively (P<0.05). The most common adverse event was bearable injection pain, and no other side effects were detected
To conclude intramatricial secukinumab injection is safe and effective in the treatment of NP, and the clinical efficacy in nail bed is superior to nail matrix.
- He F, Long F, Zhang Z, Xia R, Lu Y, Yin Z. Intramatricial injection of anti-IL-17A antibody for 6 nail psoriasis patients. Clin Exp Dermatol. 2021 Sep 12. doi: 10.1111/ced.14933.
- Dogra A, Arora AK. Nail psoriasis: the journey so far. Indian J Dermatol. 2014 Jul;59(4):319-33. doi: 10.4103/0019-5154.135470.
MBBS
Dr Manoj Kumar Nayak has completed his M.B.B.S. from the prestigious institute Bangalore medical college and research institute, Bengaluru. He completed his M.D. Dermatology from AIIMS Rishikesh. He is actively involved in the field of dermatology with special interests in vitiligo, immunobullous disorders, psoriasis and procedural dermatology. His continued interest in academics and recent developments serves as an inspiration to work with medical dialogues.He can be contacted at editorial@medicaldialogues.in.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751